• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Lucentis (ranibizumab injection)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Lucentis (ranibizumab injection)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Lucentis (ranibizumab) is a therapeutic antibody fragment designed to inhibit vascular endothelial growth factor A (VEGF-A), a protein that plays a critical role in ocular angiogenesis. Blocking VEGF-A can decrease abnormal new blood vessel formation and the resultant leaking of serum into the retina.

    Lucentis is specifically indicated for diabetic macular edema.

    Lucentis is supplied as a solution for intravitreal injection. The recommended dose of Lucentis for diabetic macular edema is 0.3 mg (0.05 mL of 6 mg/mL solution) administered once a month (approximately 28 days).

    Clinical Results

    FDA Approval
    The FDA approval of Lucentis for diabetic macular edema was based on two randomized, double-masked, three-year studies, DME1 and DME2. A total of 759 subjects were enrolled and received Lucentis 0.3 mg (n=250); Lucentis 0.5 mg (n=252) or placebo (n=257); 582 (77%) subjects completed through Month 36. The studies were placebo controlled through Month 24. From Months 25 through 36, subjects who previously received placebo were eligible to receive monthly Lucentis 0.5 mg and subjects originally randomized to monthly Lucentis 0.3 mg or 0.5 mg continued to receive their assigned dose. The study was not designed to compare the two doses of Lucentis, but each dose against the control group. Compared to monthly Lucentis 0.3 mg, no additional benefit was observed with monthly treatment with Lucentis 0.5 mg. The data are from the 0.3 mg arm and were measured at Month 24. The results are as follows:
    DME1
    Gain of >15 letters in visual acuity: Lucentis 34%; placebo 12%
    Loss of <15 letters in visual acuity: Lucentis 98%; placebo 92%
    Mean change in visual acuity (letters): Lucentis 10.9; placebo 2.3
    DME2
    Gain of >15 letters in visual acuity: Luncentis 45%; placebo 18%
    Loss of <15 letters in visual acuity: Lucentis 98%; placebo 90%
    Mean change in visual acuity (letters): Lucentis 12.5; placebo 2.6

    Visual acuity outcomes observed at Month 24 in subjects treated with Lucentis 0.3 mg were maintained with continued treatment through Month 36 in both DME studies. Subjects in the placebo arms who received Lucentis 0.5 mg beginning at Month 25 achieved lesser visual acuity gains compared to subjects who began treatment with Lucentis at the beginning of the studies.

    Side Effects

    Adverse events associated with the use of Lucentis for diabetic macular edema may include, but are not limited to, the following:

    • conjunctival hemorrhage
    • eye pain
    • vitreous floaters
    • increased IOP

    Mechanism of Action

    Lucentis (ranibizumab) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, macular edema following RVO, and DME. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

    Literature References

    Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012 Apr;119(4):789-801

    Additional Information

    For additional information regarding Lucentis or diabetic macular edema, please visit the Lucentis web page.

    Approval Date: 2012-08-01
    Company Name: Genentech
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing